Companies
(73)
AAC Clyde Space
ALM Equity
Alzinova
Arion Bank
Arlandastad Group
Ascelia Pharma
Bactiguard
Bergman & Beving
Besqab
BioPorto
Björn Borg
Bokusgruppen
Bonava
BTS Group
Byggmästaren
CAG Group
Calviks
Carasent
CDON
Clavister
Clemondo Group
eEducation Albert
Elanders
Elicera Therapeutics
Eolus
Ependion
EQL Pharma
Faron Pharmaceuticals
FluoGuide
Gentoo Media
GiG Software
HAKI Safety
HANZA
Iconovo
Idun Industrier
InfraCom
Initiator Pharma
Intervacc
ITAB Group
Kebni
Lifecare ASA
Lindex Group
Logistri
Lumi Education Group
Lytix Biopharma
Medivir
Mentice
Micro Systemation
MilDef Group
Net Insight
Nordic LEVEL Group
Orexo
Ortoma
OssDsign
Paxman
Pierce
PowerCell
Pricer
Qualisys
Relais Group
SaltX
Scanfil
Sensys Gatso Group
Sleep Cycle
Solar Foods
Spago Nanomedical
Svedbergs Group
Taaleri
Terranor
Vertiseit
Vivesto
W5 Solutions
Waystream
Sweden
Healthcare
Near term
6-12 MONTHS
Alzinova is actively engaged in partnership discussions concerning a potential licensing agreement for ALZ-101. In our view, this represents the most important potential near-term catalyst for the story.
Long term
6+ YEARS
The long-term story for Alzinova centres on ALZ-101 demonstrating encouraging clinical data and eventually achieving market approval. The high prevalence of Alzheimer’s disease, combined with the substantial healthcare costs it entails, creates considerable market potential for disease-modifying therapies. GlobalData expects the Alzheimer’s treatment market to expand at a 23.4% CAGR through 2033.
Early-stage clinical development companies face significant risks, including failure in planned studies, regulatory hurdles, and uncertainty regarding study timing and results. Such risks are generally high at this stage of development.
Alzheimer’s disease clinical trials require lengthy follow-up periods, posing recruitment and timing risks.
The company is likely to need more capital before reaching breakeven.
Price
Fair range high value
Fair range low value
The lower end of our fair value range is derived from our SOTP model using a DCF with a WACC of 22%, reflecting a scenario where the company delivers on our expectations but broader sentiment towards biotech remains subdued. The upper end, based on a WACC of 18%, assumes the same operational performance but with improving sector sentiment. We apply a relatively high WACC to capture the financing risk overhang, as the company will likely need to raise additional capital to initiate its Phase II trial should a partnership agreement not materialise.
We use a sum-of-the-parts approach in our valuation of Alzinova, with different DCFs for the upper end and lower end of the fair value range. In our model, we project peak sales of USD3.2bn for ALZ-101 in Alzheimer's disease. We assign the project a 12% likelihood of approval (LoA). Due to the absence of completed clinical trials, we have not yet included ALZ-201 in our valuation model.
About DNB Carnegie Access
DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.
Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.
Private Banking
Tailored wealth management. Your financial future, personalized.
Montrose
A digital investment platform designed for passionate investors.
DNB Carnegie
Leading Nordic investment bank and wealth management.
© Copyright DNB Carnegie Investment Bank AB